Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Nubeqa (darolutamide)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Bayer, Orion Corp

Drug class:

Androgen receptor inhibitor

Related drugs:

‹

enzalutamide capsule (78)

bicalutamide (13)

SID 3712502 (1)

rezvilutamide (0)

enzalutamide tablet (0)

enzalutamide capsule (78)

bicalutamide (13)

SID 3712502 (1)

rezvilutamide (0)

enzalutamide tablet (0)

›

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	darolutamide Sensitive: C3 – Early Trials darolutamide Sensitive : C3	darolutamide Sensitive: C3 – Early Trials darolutamide Sensitive : C3
AR L329W	Prostate Cancer	AR L329W	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR H100Q	Prostate Cancer	AR H100Q	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR D891H	Prostate Cancer	AR D891H	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR amplification	Prostate Cancer	AR amplification	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR T878A	Prostate Cancer	AR T878A	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR H875Y	Prostate Cancer	AR H875Y	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR L702H	Prostate Cancer	AR L702H	Prostate Cancer	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3	darolutamide Resistant: C3 – Early Trials darolutamide Resistant : C3
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	darolutamide + ONC201 Resistant: D – Preclinical darolutamide + ONC201 Resistant : D	darolutamide + ONC201 Resistant: D – Preclinical darolutamide + ONC201 Resistant : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	darolutamide Sensitive: D – Preclinical darolutamide Sensitive : D	darolutamide Sensitive: D – Preclinical darolutamide Sensitive : D
PTEN underexpression	Prostate Cancer	PTEN underexpression	Prostate Cancer	copanlisib + darolutamide Sensitive: D – Preclinical copanlisib + darolutamide Sensitive : D	copanlisib + darolutamide Sensitive: D – Preclinical copanlisib + darolutamide Sensitive : D